Gourt > Health > Pharmacy > Drugs and Medications > E > Entacapone
Entacapone (INN) (IPA: ) is a catechol-O-methyl transferase inhibitor for the treatment of Parkinson's disease. When administered in conjunction with dopaminergic agents such as L-DOPA, entacapone increases the bioavailability of these compounds by facilitating their passage across the blood-brain barrier.
It is a member of the class of nitrocatechols.
The most frequent undesirable effects caused by entacapone relate to the increased effects of L-DOPA, such as involuntary movements (dyskinesias).These occur most frequently at the beginning of entacapone treatment. Others common side effects are gastrointestinal problems, including diarrhoea, nausea and abdominal pains. The substance may cause urine to turn reddish-brown. This is a harmless side effect and is not a cause for concern. In studies with entacapone, some people have reported experiencing a dry mouth.
More on [ Entacapone ]
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial: European Jou... http://t.co/C6Q00jjp #neuro
MDLinx (Sandeep Pulim MD) Tue, 20 Dec 2011 06:35:07 -0000
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial: European Jou... http://t.co/C6Q00jjp #neuro
#tedmed #EFNS #kyhc Levodopa infusion combined with entacapone or tolcapone in Parkinson di... http://t.co/TZ07O9e3 #futuremed #gimh #md
arab_medicine (arab medicine) Mon, 19 Dec 2011 12:34:21 -0000
#tedmed #EFNS #kyhc Levodopa infusion combined with entacapone or tolcapone in Parkinson di... http://t.co/TZ07O9e3 #futuremed #gimh #md
Comtan (entacapone) - Novartis - Official pharmaceutical site for this drug used in the treatment of Parkinson's Disease as an adjunct to levodopa/carbidopa therapy.
Food and Drug Administration (FDA) - Comtan Consumer Information - Patient FAQ in html format with a link to approved labeling (as pdf).
Meta Description: [ Consumer Information Sheet ]
